Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02347423
Other study ID # VIPV-05
Secondary ID 2014-003449-88
Status Completed
Phase Phase 2
First received
Last updated
Start date February 2015
Est. completion date September 26, 2015

Study information

Verified date November 2018
Source Statens Serum Institut
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The background of the present clinical trial is the overall aim of the World Health Organization (WHO) to obtain eradication of polio in the world. As part of this overall plan, inactivated polio vaccine (IPV) against poliovirus types 1, 2 and 3, at an affordable price, needs to be available in low resource third world countries. The intention of the present phase II clinical trial is to determine if reduced dose(s) of IPV-Al SSI are safe in the target population and do not decrease the immunogenicity clinically significantly compared to full dose IPV Vaccine SSI. The infants will receive three doses of one of the trial vaccines according to the WHO Expanded Program on Immunization (EPI) schedule of 6, 10 and 14 weeks of age.

A total of 824 healthy infants will be included in the trial.


Description:

The trial is a phase II, dose investigation, parallel and multi-group, observer-blind, randomised, controlled, multicentre and non-inferiority trial.

Three investigational reduced dose adjuvated IPV-Al SSI vaccines and full dose IPV SSI vaccine will be investigated in four parallel groups:

- 1/3 IPV-Al SSI

- 1/5 IPV-Al SSI

- 1/10 IPV-Al SSI

- IPV Vaccine SSI (comparator)

At Visit 1 (screening and 1st vaccination visit), written informed consent is obtained and the subject's eligibility is assessed according to the pre-specified in-/exclusion criteria, including measurement of axillary temperature. If the subject is included, a pre-vaccination blood sample is taken for polio antibody determinations, and the subject is randomly allocated into one of the four groups to be vaccinated.

The subject is observed for ½ an hour after the injection of the investigational medical product (IMP) and any immediate adverse events observed are to be recorded. A diary, thermometer and ruler are handed out to the parents/guardians so that they can measure daily the injection site reactions and the axillary temperature the first 3 days and record any adverse event until the next visit.

At Visit 2 (2nd vaccination visit), 28-42 days after Visit 1, contraindications are reviewed, the 2nd vaccination is given, the diary is collected and adverse events and concomitant medications are recorded in the eCRF. A new diary is handed out.

At Visit 3 (3rd vaccination and blood sample visit), 28-42 days after Visit 2, a blood sample for immunogenicity assessment is taken, contraindications are reviewed, the 3rd vaccination is given, the diary is collected and adverse events and concomitant medications are recorded in the eCRF. A new diary is handed out.

At Visit 4 (blood sample visit), 28-42 days after Visit 3, a blood sample for immunogenicity assessment is taken, the diary is collected, and adverse events and concomitant medications are recorded in the eCRF. The trial termination form is completed.


Recruitment information / eligibility

Status Completed
Enrollment 824
Est. completion date September 26, 2015
Est. primary completion date September 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 42 Days to 49 Days
Eligibility Inclusion Criteria:

1. Infants of 6 weeks of age (+7 days) on date of first vaccination

2. Healthy assessed from medical history and physical examination

3. One parent/guardian has been properly informed about the trial and has signed the informed consent form

4. One parent/guardian grants access to the infant's trial related medical records

5. One parent/guardian is likely to comply with trial procedures

Exclusion Criteria:

1. Vaccinated with poliovirus vaccine (OPV or IPV), other than the trial vaccines, prior to inclusion or planned during the trial (e.g. on national polio immunisation days)

2. OPV vaccination or known exposure to poliovirus in household (living together) within 3 month prior to inclusion or planned during the trial

3. Has a sibling who is =5 years of age, and for whom OPV vaccination is planned during the trial

4. Low birth weight (< 2,500 g)

5. Known or suspected immunodeficiency (e.g. HIV, leukaemia, lymphoma) or family history of congenital or hereditary immunodeficiency

6. Severe uncontrolled chronic disease (e.g. neurologic, pulmonary, gastrointestinal, hepatic, renal or endocrine)

7. Known or suspected allergy to vaccine constituents (e.g. hypersensitivity to formaldehyde)

8. Acute severe febrile illness at day of vaccination deemed by the investigator to be a contraindication for vaccination

9. Uncontrolled coagulopathy or blood disorder contraindicating intramuscular injections or blood sampling

10. Treatment with a product which is likely to modify the immune response (e.g. blood products and immunoglobulins) prior to inclusion or planned during the trial

11. Participating in another clinical trial

12. Not suitable for inclusion in the opinion of the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Primary series of immunisation comprised by 3 vaccinations IPV-Al SSI

IPV Vaccine SSI


Locations

Country Name City State
Dominican Republic Hospital Maternidad Nuestra de la Altagracia Santo Domingo

Sponsors (4)

Lead Sponsor Collaborator
Statens Serum Institut Bill and Melinda Gates Foundation, Larix A/S, Quintiles, Inc.

Country where clinical trial is conducted

Dominican Republic, 

Outcome

Type Measure Description Time frame Safety issue
Primary For each of the 3 poliovirus types 1, 2 and 3, for the IPV-Al and IPV Vaccine SSI vaccines to evaluate: Type specific seroconversion rates based on baseline and 4 weeks post 3rd vaccincation Change from baseline to 4 weeks post 3rd vaccincation
Secondary Type-specific geometric mean titers (GMTs) 4 weeks post 3rd vaccination for each vaccine
Secondary Type-specific seroprotection rates (titers = 1/8) 4 weeks post 3rd vaccination for each vaccine
Secondary Type-specific reverse cumulative titer distribution curves based on pre-vaccination and 4 weeks post 3rd vaccination serum titers for each vaccine 4 weeks post 3rd vaccination for each vaccine
Secondary Adverse events following the vaccinations for each vaccine From inclusion to 4 weeks post 3rd vaccincation
See also
  Status Clinical Trial Phase
Completed NCT04989231 - An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses
Completed NCT00352963 - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). Phase 3
Recruiting NCT03890497 - Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV When Administered at 9-13 Months of Age in Bangladesh Phase 4
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Completed NCT04693286 - Clinical Trial of Novel OPV2 Vaccine Phase 2
Completed NCT02847026 - Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study Phase 4
Completed NCT02189811 - Polio End-game Strategies - Poliovirus Type 2 Challenge Study Phase 4
Completed NCT01444781 - Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants Phase 3
Completed NCT01214889 - Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. Phase 3
Completed NCT00879827 - Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants Phase 3
Completed NCT01457495 - Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly Phase 2
Completed NCT02853929 - Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Phase 4
Completed NCT03614702 - Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV Phase 3
Terminated NCT04063150 - Immunogenicity of Intramuscular and Intradermal IPV Phase 4
Completed NCT04614597 - A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China
Completed NCT03239496 - A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV Phase 3
Completed NCT04544787 - A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates Phase 2
Completed NCT02985320 - Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine Phase 1/Phase 2
Completed NCT02291263 - Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine Phase 3
Completed NCT02274285 - DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants Phase 3